Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
Rhea-AI Summary
Exicure (Nasdaq:XCUR) received a Nasdaq notice on June 5, 2026 for not meeting the $2.5 million minimum stockholders’ equity requirement under Rule 5550(b)(1). Reported equity was about $2.1 million as of March 31, 2026, and alternative listing standards are also not satisfied.
The notice does not immediately affect listing. Exicure has until July 20, 2026 to submit a compliance plan and may receive up to 180 days from the notice date to regain compliance. The company is evaluating options and continues to pursue its hematologic disease program.
Positive
- Nasdaq notice has no immediate effect on XCUR Nasdaq Capital Market listing
- Company has 45 days, until July 20, 2026, to submit compliance plan
- Potential extension of up to 180 days from notice date to regain compliance
- Current management implemented cost-reduction and restructuring initiatives
- Termination of substantially all non-essential legacy consulting arrangements
- Lead program in hematologic diseases continues in clinical development
Negative
- Stockholders’ equity approximately $2.1 million vs. $2.5 million Nasdaq minimum
- Company currently fails alternative market value and net income listing standards
- Equity and financial position impacted by executive separation-related expenses
- Long-term consulting arrangements contributed to pressure on stockholders’ equity
News Market Reaction – XCUR
In the Jun 11 session, XCUR gained 2.17%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.5% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the “Company”) today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on June 5, 2026 indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of
As reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, the Company reported stockholders’ equity of approximately
The Company believes that its financial position and stockholders’ equity were impacted in part by executive separation-related expenses and obligations under certain long-term consulting arrangements entered into prior to the current management team's appointment. Under the current management team, the Company has implemented significant cost-reduction and restructuring initiatives, including the termination of substantially all non-essential legacy consulting arrangements.
The notification has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market. Under Nasdaq rules, the Company has 45 calendar days, or until July 20, 2026, to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, Nasdaq may grant an extension of up to 180 calendar days from the date of the notice to regain compliance.
The Company intends to submit a compliance plan within the prescribed timeframe and is evaluating various alternatives to regain compliance with the applicable listing requirements.
About Exicure, Inc.
Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value. In January 2025, it acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases. The Company’s lead program in development is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. For more information, visit www.exicuretx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the Company’s plans to regain compliance with Nasdaq listing requirements. Actual results may differ materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation to update any forward-looking statements except as required by law.
Media Contact:
Exicure, Inc.
pr@exicuretx.com
